We are live on ! Find out more
KTTA icon

Pasithea Therapeutics
KTTA

11 hedge funds and large institutions have $217K invested in Pasithea Therapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

119% more capital invested

Capital invested by funds: $99.1K → $217K (+$118K)

38% more funds holding

Funds holding: 8 → 11 (+3)

2.18% less ownership

Funds ownership: 6.22% → 4.04% (-2.2%)

Holders
11
Holders Change
+3
Holders Change %
+37.5%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AI
AdvisorShares Investments
Maryland
+$153K
2
Citadel Advisors
Citadel Advisors
Florida
+$51.2K
3
UBS Group
UBS Group
Switzerland
+$41.3K
4
LPL Financial
LPL Financial
California
+$10.9K
5
Raymond James Financial
Raymond James Financial
Florida
+$1.73K

Top Sellers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
-$17.8K
2
TRCT
Tower Research Capital (TRC)
New York
-$2.19K

KTTA Hedge Fund Activity: Q2 2025 in Review

11 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q2 2025, worth a combined $217K — up 119% from $99.1K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new KTTA positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was AdvisorShares Investments, adding an estimated $153K. The largest seller was Citigroup, exiting entirely with an estimated $17.8K sold.

  • 11 institutional investors held Pasithea Therapeutics (KTTA) as of Q2 2025, up from 8 in Q1 2025.
  • Funds reported $217K of Pasithea Therapeutics stock for Q2 2025, up 119% quarter-over-quarter.
  • 4 funds opened new Pasithea Therapeutics positions in Q2 2025 and 1 closed out, a net change of +3 holders.
  • The largest Pasithea Therapeutics buyer in Q2 2025 was AdvisorShares Investments, an estimated $153K added.
  • The largest Pasithea Therapeutics seller in Q2 2025 was Citigroup, an estimated $17.8K sold.

Based on aggregated 13F filings for Q2 2025.